Skip to main content
. 2022 Jul 9;12:11718. doi: 10.1038/s41598-022-15801-7

Table 1.

Patient characteristics for analyzed cohort.

Patient # Age (years) Tumor type Tumor grade Experimental arm ALN status RCB index
1 46 ER + /PR +  IB Durvalumab + Olaparib Negative 1.94
2 48 HER2 +  IIIA Pertuzumab + Trastuzumab Negative 0
3 50 ER + /PR +  IIB SD-101 + Pembrolizumab Negative 1.48
4 44 TNBC IIIB SD-101 + Pembrolizumab Positive 3.32
5 54 ER + /PR +  IIA Control (Paclitaxel only) Positive 3.15
6 58 ER + /PR +  IIIA Cemiplimab + REGN3767 Negative 2.60